Lonza strengthens ADC offering with Synaffix acquisition

Published on June 16, 2023

Lonza has acquired Synaffix B.V., a biotech company focused on commercializing its clinical-stage technology platform for the development of antibody drug conjugates (ADCs).

Continue reading on website
Other news

InDex Pharmaceuticals signs licence deal with Viatris for cobitolimod

June 16, 2023
InDex Pharmaceuticals has entered a licence deal with Viatris Pharmaceutical Japan for the development and commercialisation of cobitolimod in Japan to treat ulcerative colitis (UC).Under the terms of the deal, InDex will receive a $10m upfront payment from Viatris Japan for the exclusive commercialisation rights for cobitolimod in the country.The company will also be entitled to receive up to $40

Lonza to acquire Synaffix to strengthen ADC development

June 16, 2023
Synaffix’s technology platform is intended to enhance and extend Lonza’s integrated ADC services